Clinical Trial Update: Prospective Clinicogenomic Program [Phase 4]

View source ↗

Summary

A Phase 4 prospective clinicogenomic program in progress for non-small cell lung cancer and small-cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC) | Phase 4 | Status: COMPLETED